MORABITO, FORTUNATO
 Distribuzione geografica
Continente #
EU - Europa 225
NA - Nord America 217
AS - Asia 31
AF - Africa 3
Totale 476
Nazione #
US - Stati Uniti d'America 217
IT - Italia 191
CN - Cina 25
FI - Finlandia 9
DE - Germania 8
AT - Austria 7
NL - Olanda 7
CZ - Repubblica Ceca 2
ET - Etiopia 2
JP - Giappone 2
KR - Corea 2
SG - Singapore 2
GB - Regno Unito 1
SN - Senegal 1
Totale 476
Città #
Florence 125
Ashburn 63
Shanghai 25
Sesto Fiorentino 23
Noto 22
Washington 19
Ogden 11
Helsinki 9
Naaldwijk 7
Vienna 7
New York 4
Palmi 3
Addis Ababa 2
Bari 2
Gualdo Tadino 2
Milan 2
Rome 2
Seoul 2
Tokyo 2
West Jordan 2
Bologna 1
Brooklyn 1
Cirò Marina 1
Dakar 1
Rende 1
Santa Barbara 1
Seattle 1
Udine 1
Totale 342
Nome #
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 22
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 21
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 21
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 21
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 20
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 20
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 20
Iron chelation therapy 19
Elotuzumab in multiple myeloma 19
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 18
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 18
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 18
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 17
Myelodysplastic syndromes with ring sideroblasts 16
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 16
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 16
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 16
Belantamab mafodotin in multiple myeloma 16
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 15
Teclistamab-cqyv in multiple myeloma 15
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 13
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 13
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 12
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 12
Isatuximab in multiple myeloma 11
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 11
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 10
Acalabrutinib in chronic lymphocytic leukemia 10
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 10
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 9
Ivosidenib in acute myeloid leukemia 9
Glasdegib for the treatment of acute myeloid leukemia 6
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 5
Zanubrutinib for the treatment of chronic lymphocytic leukemia 4
Selinexor in multiple myeloma 3
Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period 3
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 3
Venetoclax in acute myeloid leukemia 3
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 3
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 2
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia 2
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity 2
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 1
Tagraxofusp in myeloid malignancies 1
Totale 522
Categoria #
all - tutte 5.340
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.340


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202369 0 0 0 0 0 0 30 4 4 4 21 6
2023/2024453 9 14 121 91 53 90 29 21 20 5 0 0
Totale 522